
News|Articles|June 1, 2002
Long-term trials show good response to new anti-RA biologic
In studies reported this month at the European League Against Rheumatism meeting in Stockholm, the anti-TNF antibody adalimumab (D2E7) for rheumatoid arthritis is showing good long-term results, even in patients for whom other disease modifying antirheumatic drugs (DMARDs) have failed.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
3
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























